CD8A and cancer: Another adjuvant, PapMVa, could significantly promote the release of chemokines and pro-inflammatory cytokines and increase the infiltration of immune cells at tumor sites, promoting a significant increase in cancer-specific CD8+ T-cell numbers but a notable decrease in the proportion of myeloid suppressor cells after intertumoral administration.